Concert Pharmaceuticals Inc. (NASDAQ:CNCE) shares fell 3.5% during mid-day trading on Thursday . The stock traded as low as $11.25 and last traded at $11.32, with a volume of 54,870 shares. The stock had previously closed at $11.73.

Several brokerages recently issued reports on CNCE. Brean Capital reissued a “buy” rating on shares of Concert Pharmaceuticals in a report on Saturday, April 30th. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 4th. Finally, Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a report on Friday, July 1st. They issued a “buy” rating and a $23.00 price objective for the company. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $26.43.

The company has a market capitalization of $258.15 million and a price-to-earnings ratio of 13.95. The company has a 50 day moving average price of $11.94 and a 200-day moving average price of $13.53.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its earnings results on Thursday, May 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.18. Equities analysts forecast that Concert Pharmaceuticals Inc. will post ($2.16) EPS for the current fiscal year.

In related news, CEO Roger D. Tung bought 19,610 shares of the stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average price of $10.55 per share, for a total transaction of $206,885.50. Following the acquisition, the chief executive officer now owns 538,965 shares in the company, valued at approximately $5,686,080.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. California Public Employees Retirement System increased its stake in shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 22.0% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 103,700 shares of the company’s stock after buying an additional 18,700 shares during the period. California Public Employees Retirement System owned approximately 0.47% of Concert Pharmaceuticals worth $1,967,000 at the end of the most recent quarter.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.